arrow
D

Daoqi You

Memorial Sloan Kettering Cancer Center
H指数:21
被引数:3,780

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma

单细胞蛋白质活性分析揭示了MYOD1突变型横纹肌肉瘤中异常的肌发生以及IGF2-PI3K通路的依赖性。

2026-02-270
OA
Author Correction: Clonal evolution during metastatic spread in high-risk neuroblastoma

作者更正:高危神经母细胞瘤转移扩散过程中的克隆进化

2025-08-050
PRE
Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma
2023-10-098
OAAI
Clonal evolution during metastatic spread in high-risk neuroblastoma
2023-05-1112
OA
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2023-04-169
OA
Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors
MED
IF11.8
2022-11-017
OAAI
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma

ATR在腺泡状横纹肌肉瘤中的靶向治疗作用

2022-07-258
OAAI
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
2022-07-1513
OAAI
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm
2022-02-146
OAAI
Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor
2021-03-2225
OA
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer
2019-05-0110
OAAI
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2018-12-03148
OAAI
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
2017-03-01173
OAAI